Comparative Pharmacology
Head-to-head clinical analysis: EVEX versus LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVEX versus LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL.
EVEX vs LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen receptor agonist; binds to and activates nuclear estrogen receptors, leading to gene transcription and cellular effects in target tissues.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; levonorgestrel alters cervical mucus and endometrial lining to prevent fertilization and implantation.
0.625-1.25 mg orally once daily; or 0.3-0.625 mg vaginally once daily for 21 days with 7 days off.
One tablet containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol (or 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo or ethinyl estradiol 0.01 mg alone. For extended-cycle regimens, dosing may be continuous for up to 84 days.
None Documented
None Documented
Terminal elimination half-life is 12-24 hours, with a mean of approximately 18 hours. Due to significant enterohepatic recirculation, the half-life may be prolonged in patients with hepatic impairment or when administered with drugs that inhibit recirculation.
Levonorgestrel: ~25 hours; Ethinyl estradiol: ~13 hours. Steady-state achieved within 5-7 days; clinical efficacy maintained by daily dosing.
Primarily hepatic metabolism with renal excretion of metabolites; approximately 60% of a dose is excreted in urine as conjugates (glucuronides and sulfates) and 30% in feces via biliary elimination. Less than 5% is excreted unchanged in urine.
Levonorgestrel: 45% renal, 32% fecal; Ethinyl estradiol: 40% renal, 60% fecal. Both undergo enterohepatic recirculation.
Category C
Category D/X
Estrogen
Estrogen